News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Testosterone Biotech Clarus Therapeutics Files For A $86 Million IPO


5/27/2014 8:27:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Clarus Therapeutics, a biotech awaiting FDA approval for an oral testosterone replacement therapy, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Northbrook, IL-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol CLRS. Another IPO filer, Claire's (CLRS.RC), applied to list on the NYSE under the same symbol in its May 2013 filing.

Help employers find you! Check out all the jobs and post your resume.

Read at Nasdaq
Read at RTT News


comments powered by Disqus
Nasdaq
RTT News
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES